Phase II study of olaparib plus ATR inhibitor ceralasertib in patients with metastatic breast cancer and germline BRCA1/2 pathogenic variants who progressed on prior PARP inhibitor therapy.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Banu Arun, Adaeze Nwosu Iheme, Nuhad K. Ibrahim, Rachel M. Layman, Ajit Kumar Bisen, David Luis Ramirez, Madison H. Williams, Giancarlo Moscol, Vicente Valero, Oluchi Oke, Azadeh Nasrazadani, Mariana Chavez Mac Gregor, Clinton Yam, Angelica M. Gutierrez, Cynthia Tamez, Katharina Schlacher, John A. Tainer, Simon Smith, Junjie Chen, Constance T. Albarracin
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162559898
Cites:
Cited by:
Related to: